产品中心
产品展示

  您当前的位置:首页 » 产品展示 » » CRL-2630 Farage 人B淋巴瘤细胞系.

产品名称: CRL-2630 Farage 人B淋巴瘤细胞系.
产品型号: CRL-2630
品牌: 995
产品数量:
产品单价: 面议
日期: 2024-09-04

CRL-2630 Farage 人B淋巴瘤细胞系.的详细资料

 CRL-2630 Farage 人B淋巴瘤细胞系
ATCC® Number: CRL-2630™     Price: $338.00
Designations: Farage
Depositors:  H Ben-Bassat
Biosafety Level: 2 [Cells contain Epstein-Barr virus (EBV) ]
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Homo sapiens (human)
Morphology: lymphoblast

Source: Disease: non-Hodgkin's B cell lymphoma 
Derived from metastatic site: lymph node 
Cell Type: B lymphocyte;
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
 
Antigen expression: CD10 +/-; CD11a + (LFA-1); CD19 +; CD20 +; CD21 +; CD22 +; CD23 +; CD29 (VLA-4) +; CD38 +; CD39 +; CD40 +; CD44 +; CD54 + (ICAM-1); CD58 + (LFA-3); CD23 -; HLA DR + [55508] [53289]
DNA Profile (STR): Amelogenin: X 
CSF1PO: 11,12 
D13S317: 11,13 
D16S539: 11,12 
D5S818: 12 
D7S820: 12 
THO1: 8,9 
TPOX: 9 
vWA: 14,15
Cytogenetic Analysis: trisomy of chromosome 11 [53289]
Age: *****
Gender: female
Ethnicity: White
Comments: The Farage cell line was adapted to culture in 1990 from a lymph node biopsy of a patient with diffuse large cell non-Hodgkin's lymphoma (DLCL). [55508
The cells do not express surface or cytoplasmic immunoglobulin. [55508
Exposure to IL-4 augmented the concentrations of CD23, CD54, and CD58 but diminished the expression of CD21, CD22, and CD38. Incubation with IL-4 for 6 to 8 days led to increased expression of CD11a, CD39, CD40, and to disappearance of CD21 and CD38. [55510] [55508
Exposure of Farage cells to phorbol 12-myristate 13-acetate (PMA) down-regulated CD21 and CD23 expression. [55509
They do not express the terminal deoxynucleotydyl transferase gene (TdT), nor the recombination activating genes RAG-1 and RAG-2, known as markers of the pre-B cell stage. These results show that Farage represents a mature B-cell rather than a pre-B cell. [53288
The cells are positive for Epstein-Barr virus (EBV). [53289
mature B cell
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) 
Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension in fresh medium at 3 - 5 X 10 exp5 viable cells/ml. 
Maintain cultures at cell concentrations between 3 X 10 exp5 and 3 X 10 exp6 viable cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Doubling Time: 24 to 36 hrs
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 53288: Baruch M, et al. Molecular characterization of an unusual non-Hodgkin's B-lymphoma cell line ("Farage") lacking the ability to produce immunoglobulin polypeptide chains. Leuk. Lymphoma 21: 485-495, 1996. PubMed: 9172815
53289: Gabay C, et al. Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur. J. Immunol. 63: 180-191, 1999. PubMed: 10485273
55508: Shubinsky G, et al. The effect of IL-4 on the phenotype of a human B-cell lymphoma line (Farage) lacking immunoglobulin expression. Immunol. Lett. 36: 37-42, 1993. PubMed: 8344715
55509: Shubinsky G, et al. Pathways controlling the expression of surface CD21 (CR2) and CD23 (Fc(epsilon)IIR) proteins in human malignant B cells. Leuk. Lymphoma 25: 521-530, 1997. PubMed: 9250823
55510: Shubinsky G, Schlesinger M. Kinetics of the pleiotropic effect of interleukin 4 on the surface properties of human B-lymphoma cells. Leuk. Lymphoma 15: 333-340, 1994. PubMed: 7866283
55511: Shubinsky G. The mechanism of interleukin 4-induced down-regulation of CD38 on human B cells. Cell. Immunol. 10: 87-95, 1996. PubMed: 8871604